Special Issue

Molecular Targets and Therapeutic Pathways in Cancer

Message from the Guest Editors

Cancer remains one of the leading causes of mortality worldwide, making continued innovation in the development of therapeutic options a necessity. This Special Issue, "Molecular Targets and Therapeutic Pathways in Cancer", aims to highlight recent advances in the identification of novel molecular targets and the elucidation of signaling pathways that drive the initiation. progression, and resistance of tumors. With the rapid expansion of genomics, proteomics, and highthroughput screening technologies, researchers are now better equipped to unravel the complex biology underlying cancer and translate these insights into more precise and effective therapies. We welcome original research articles, reviews, and perspectives that explore oncogenic signaling networks, targeted therapy development, resistance mechanisms, and emerging strategies such as synthetic lethality, immunomodulation, and drug repurposing. By showcasing cutting-edge work in this area, this Special Issue aims to foster collaboration and innovation at the interface of basic science and clinical translation.

Guest Editors

Dr. Ashish H. Shah

Neurological Surgery, University of Miami Miller School of Medicine, Miami, FL, USA

Dr. Deepa Seetharam

Department of Neurosurgery, Section of Virology and Immunotherapy, Sylvester Comprehensive Cancer Center, University of Miami Miller School of Medicine, Miami, FL 33136, USA

Deadline for manuscript submissions

31 October 2026



Cancers

an Open Access Journal by MDPI

Impact Factor 4.4
CiteScore 8.8
Indexed in PubMed



mdpi.com/si/243996

Cancers
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
cancers@mdpi.com

mdpi.com/journal/cancers





Cancers

an Open Access Journal by MDPI

Impact Factor 4.4 CiteScore 8.8 Indexed in PubMed



About the Journal

Message from the Editor-in-Chief

Cancers is an international online journal addressing both clinical and basic science issues related to cancer research. The journal is publishing in Open Access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

Editor-in-Chief

Prof. Dr. Samuel C. Mok.

Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Oncology) / CiteScore - Q1 (Oncology)

